Moxifloxacin
- Generic Name
- Moxifloxacin
- Brand Names
- Avelox, Moxeza, Vigamox
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24FN3O4
- CAS Number
- 151096-09-2
- Unique Ingredient Identifier
- U188XYD42P
- Background
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
- Indication
For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
- Associated Conditions
- Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections
- Associated Therapies
- -
A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2017-08-23
- Last Posted Date
- 2020-02-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 45
- Registration Number
- NCT03258515
- Locations
- 🇺🇸
Research Site, Baltimore, Maryland, United States
Acute Appendicitis and Microbiota - Etiology of Appendicitis and Antibiotic Therapy Effects
- Conditions
- Interventions
- First Posted Date
- 2017-08-22
- Last Posted Date
- 2020-11-10
- Lead Sponsor
- Turku University Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT03257423
- Locations
- 🇫🇮
Turku University Hospital, Turku, Finland
Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery
- First Posted Date
- 2017-08-09
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Jason Ahee, M.D.
- Target Recruit Count
- 60000
- Registration Number
- NCT03244072
- Locations
- 🇺🇸
Zion Eye Institute, Saint George, Utah, United States
Optimizing the Antibiotic Treatment of Uncomplicated Acute Appendicitis
- Conditions
- Interventions
- First Posted Date
- 2017-08-02
- Last Posted Date
- 2020-11-12
- Lead Sponsor
- Turku University Hospital
- Target Recruit Count
- 552
- Registration Number
- NCT03236961
- Locations
- 🇫🇮
Turku University Hospital, Turku, Finland
A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" Episodes
- Conditions
- Interventions
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2020-08-10
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT03187301
- Locations
- 🇺🇸
Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States
🇺🇸The Parkinson's and Movement Disorder Institute, Fountain Valley, California, United States
🇺🇸Atlanta Center for Medical Research, Atlanta, Georgia, United States
Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)
- Conditions
- Interventions
- First Posted Date
- 2016-12-02
- Last Posted Date
- 2019-05-22
- Lead Sponsor
- Laboratorios Sophia S.A de C.V.
- Target Recruit Count
- 150
- Registration Number
- NCT02980523
- Locations
- 🇲🇽
Unidad Medica "Grupo Pediátrico", Guadalajara, Jalisco, Mexico
Effect of Imeglimin on QT/QTc Intervals in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Poxel SA
- Target Recruit Count
- 55
- Registration Number
- NCT02924337
- Locations
- 🇬🇧
Hammersmith Medicines Research (HMR), London, United Kingdom
Safety and Efficacy Study of Different DAV132 Dose Regimens in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2016-09-28
- Last Posted Date
- 2017-09-12
- Lead Sponsor
- Da Volterra
- Target Recruit Count
- 150
- Registration Number
- NCT02917200
- Locations
- 🇫🇷
Eurofins Optimed, Gières, France
A Thorough QTc Trial Evaluating the Effect of SNAC on Cardiac Repolarisation in Healthy Male Subjects.
- First Posted Date
- 2016-09-22
- Last Posted Date
- 2018-01-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 84
- Registration Number
- NCT02911870
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2016-09-22
- Last Posted Date
- 2022-01-28
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT02910635
- Locations
- 🇺🇸
Covance, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.